Every 10-Q that BeyondSpring Inc. (BYSI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BYSI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BYSI filings page.
BeyondSpring Inc. reported another loss-making quarter as a clinical-stage biotech with no product revenue. For the six months ended June 30, 2026, consolidated net loss was $12.4 million, and accumulated deficit reached $411.4 million. Continuing operations held $6.5 million of cash and short-term investments and had net current liabilities of $4.3 million, resulting in a total shareholders’ deficit of $36.0 million.
Management disclosed that recurring losses, limited liquidity and negative working capital raise substantial doubt about the ability to continue as a going concern. The company is cutting spending and seeking additional capital; failure to do so could force reductions in R&D or suspension of operations. Discontinued SEED operations generated $1.0 million of collaboration revenue but a $8.3 million loss in the first half. BeyondSpring expects to collect an additional $28.07 million in tranches from the sale of SEED preferred shares while retaining a minority stake and continuing to focus its main Plinabulin oncology program.
BeyondSpring Inc. reported a consolidated net loss of $6.7 million for the three months ended March 31, 2026, compared with net income of $1.2 million a year earlier, when results were boosted by a $7.0 million gain on a SEED share sale.
Continuing operations posted a net loss of $2.4 million as research and development expenses rose to $1.1 million and general and administrative costs declined to $1.2 million. Discontinued SEED operations generated a loss of $4.3 million, reflecting ongoing investment in its targeted protein degradation platform.
Cash and cash equivalents plus short-term investments from continuing operations totaled $7.9 million as of March 31, 2026, while deferred revenue of about $29.0 million from the Hengrui collaboration remained on the balance sheet. Management expects additional cash inflows from staged sales of SEED preferred shares and is evaluating financing and strategic alternatives.
BeyondSpring Inc. filed its Q3 2025 10‑Q, showing a year‑to‑date swing to positive net income attributable to the company of $1,131, driven by a $6,986 gain on sale of subsidiary interests tied to its SEED Therapeutics divestiture plan. From continuing operations, the company reported a year‑to‑date operating loss of $6,349 as it had no revenue, with research and development at $2,915 and general and administrative at $3,434.
Cash and cash equivalents were $12,483 at September 30, 2025. Net cash used in operating activities was $14,265 year‑to‑date, offset by $15,934 provided by investing activities, including proceeds from maturities of short‑term investments and the SEED transaction. Total assets were $29,484, total liabilities $49,294, and shareholders’ deficit widened to $(19,810), reflecting high deferred revenue balances and noncontrolling interests.
The SEED plan advanced: the first closing on February 19, 2025 sold 1,730,454 Series A‑1 shares for $7,354. A second closing is scheduled no later than December 15, 2025, and a third by December 15, 2026, which would reduce BYSI’s SEED stake to 13.62% upon completion. Shares outstanding were 40,332,320 as of September 30, 2025.
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on its lead asset Plinabulin and a TPD platform carried through SEED. As of June 30, 2025 the consolidated balance sheet shows $31.0 million in total assets and $48.6 million in total liabilities, resulting in a $17.5 million shareholders' deficit (including noncontrolling interests). Cash and cash equivalents from continuing operations increased to $9.544 million.
Operationally, the company reported a consolidated net loss of $4.65 million for the quarter ended June 30, 2025 and a $3.48 million net loss for the six months. For the six months ended June 30, 2025, however, net income attributable to BeyondSpring Inc. was $2.671 million, which reflects a $6.986 million gain recognized on the first closing of the sale of subsidiary interests in SEED. The company completed a first closing that generated $7.354 million of cash proceeds and recorded gross proceeds from the multi-tranche sale agreements of approximately $35.418 million.
Cash flow activity shows $10.07 million used in operating activities and $17.15 million provided by investing activities (including maturities of short-term investments and proceeds from the SEED sale), producing a $7.08 million net increase in cash for the six months. Significant off-balance-sheet and contract items disclosed include $31.039 million upfront consideration received under the Hengrui collaboration that remains recorded as deferred revenue and a full valuation allowance on deferred tax assets with $4.573 million of gross unrecognized tax benefits.